Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis

被引：2

作者：

Chin, Peter ^{[1
]}

Chan, Andrew C. ^{[2
]}

机构：

[1] Genentech Inc, Med Affairs, One DNA Way, San Francisco, CA 94080 USA

[2] Genentech Inc, Res, One DNA Way, San Francisco, CA 94080 USA

来源：

关键词：

RITUXIMAB; PLACEBO;

D O I：

10.1021/acs.biochem.7b00796

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：474 / 476

页数：3

共 50 条

[1] Ocrelizumab: a new milestone in multiple sclerosis therapy
Mulero, Patricia
Midaglia, Luciana
Montalban, Xavier
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
[2] Ocrelizumab for multiple sclerosis
Lin, Mengbing
Zhang, Jian
Zhang, Yueling
Luo, Jiefeng
Shi, Shengliang
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (05):
[3] Ocrelizumab: A Review in Multiple Sclerosis
Syed, Yahiya Y.
CNS DRUGS, 2018, 32 (09) : 883 - 890
[4] Ocrelizumab in pediatric multiple sclerosis
Amirov, Ceren Bibinoglu
Saltik, Sema
Yalcinkaya, Cengiz
Tutuncu, Melih
Saip, Sabahattin
Siva, Aksel
Uygunoglu, Ugur
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 43 : 1 - 5
[5] Ocrelizumab for the treatment of multiple sclerosis
Bigaut, Kevin
De Seze, Jerome
Collongues, Nicolas
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (02) : 97 - 108
[6] Ocrelizumab: A Review in Multiple Sclerosis
Yvette N. Lamb
Drugs, 2022, 82 : 323 - 334
[7] Ocrelizumab: A Review in Multiple Sclerosis
Lamb, Yvette N.
DRUGS, 2022, 82 (03) : 323 - 334
[8] Ocrelizumab: A Review in Multiple Sclerosis
Yahiya Y. Syed
CNS Drugs, 2018, 32 : 883 - 890
[9] B-cell function modulation in multiple sclerosis: a new therapeutic paradigm
Chan, Andrew
Schutte, Albert Jan
FUTURE NEUROLOGY, 2014, 9 (01) : 23 - 26
[10] New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
Frau, Jessica
Coghe, Giancarlo
Lorefice, Lorena
Fenu, Giuseppe
Cocco, Eleonora
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 1093 - 1099